JHEP Reports

Article	Citations
Copyright and information	164
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives	115
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”	105
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis	90
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]	88
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD	86
Time for a globally unified chronic HBV terminology?	80
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?	79
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes	78
Statistical precision of p values: A note on “Liver fibrosis progression analyzed with AI predicts renal decline”	75
Editorial Board page	74
A small animal model of chronic hepatitis E infection using immunocompromised rats	68
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication	65
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer	62
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice	60
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging	59
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis	58
MELD 3.i: A Bayesian framework for updating the model for end-stage liver disease score	58
Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacy	57
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis	57
Predicting liver ablation volumes with real-time MRI thermometry	56
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool	55
Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort	52
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort	52
Clinical features and management for CDK4/6 inhibitor-DILI	51

What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	51
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	51
Contents	50
Unaddressed concerns of potential follow-up bias in the international PSC registry	49
Intrahepatic T cell analysis reveals Th17 and MAIT17 enrichment in primary sclerosing cholangitis	49
Integrative Multi-Omics Analysis Identifies Stellate Cell-Derived Complement Component 7 as a Predictor of Fibrosis and Liver-Related Events in MASLD Patients	48
Shunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS	48
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st	45
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data	45
Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulation	45
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation	45
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort	41
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis	41
Editorial Board page	41
Reply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”	40
Understanding virologic heterogeneity in chronic hepatitis B treatment	39
Predicting the need for early TIPS in patients with cirrhosis and ascites: More art than science	39
Editorial Board page	38
Proteome-scale autoantibody profiling in PSC: Associations with clinical phenotypes and evidence for neuroendocrine deregulations	38
Pattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials	37
Deep learning can predict cardiovascular events from liver imaging	37
Xanthine oxidase promotes hepatic lipid accumulation through high fat absorption by the small intestine	37
Failure-to-rescue as a determinant of overall survival following resection for perihilar cholangiocarcinoma	37
Contents	37
p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis	36
SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH	36
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV	36
PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle	35
Potential role of liver-resident CD3+ macrophages in HBV clearance in a mouse hepatitis B model	35
RAC1 as a novel therapeutic target for acute liver failure	34
Loss, amplification or mistiming of the daily rhythms of metabolic markers in patients with cirrhosis	34
A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium	33
Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis	33
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey	33
Arachidonic acid activates NLRP3 inflammasome in MDSCs via FATP2 to promote post-transplant tumour recurrence in steatotic liver grafts	32
Agentic AI for interdisciplinary clinical decision support in high-stakes care	32
Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice	32
PNPLA3 polymorphisms and risk of hepatic and extrahepatic outcomes in MASLD: A meta-analysis of observational studies	32
Macrophage MRC2 deficiency mitigates HFD-induced MASLD by downregulating CD147-regulated TNF-α production	32
Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways	31
Development and psychometric evaluation of the Liver Disease Stigma Scale (LDSS)	31
Spatial proteomics and cell-cell crosstalk analysis reveal PD-L1 and IL-6 interaction in human primary sclerosing cholangitis	31
lnc122 RNA prevents liver tumorigenesis in MYC-driven liver cancer	31
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study	31
Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment	31
Reply to: “Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma”	30
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis	30
Contents	30
Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy	29
Extending the Baveno VII definition of recompensation to autoimmune hepatitis: Considerations regarding treatment timing and response criteria	29

Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity	29
Application of a deep learning algorithm for the diagnosis of HCC	29
The endonuclease MCPIP1 protects against liver cancer development in a sex-dependent manner by modulating β-catenin and CREB1	29
Development of a CRE/CREB-driven HBx responsive HBV cell culture reporter system for antiviral drug evaluation	28
Monitoring of hepatitis E virus infection and replication by functional tagging of the ORF2 protein	28
Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab	28
Targeting fibrosis and steatohepatitis through the metabolism – results from the ESSENCE trial	28
Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosis	28
Corrigendum to: ‘Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia’ (JHEP Reports, Volume 6, Issue 7, July 2024, 101090)	28
Editorial Board page	28
Dual-tracer PET/CT in the management of hepatocellular carcinoma	27
Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries	27
Geography-independent mucosal microbiota alterations in primary sclerosing cholangitis persist after liver transplantation	27
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma	27
Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis	27
Regulatory T cell therapy in autoimmune liver disease and transplantation	27
Anatomical resection is associated with reduced early recurrences in HCC: A machine learning analysis	26
Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy	26
Platelets accelerate endoplasmic reticulum stress and promote hepatic steatosis	26
Cholangiocarcinoma-on-a-chip: A human 3D platform for personalised medicine	26
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis	26
CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis	26
Reply to: “Trans-splenic anterograde coil assisted transvenous obliteration vs. retrograde transvenous obliteration: Are we heading the right way?”	25
Disparities in transplant access and outcomes after first cirrhosis decompensation in alcohol-related liver disease	25
IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers	25
Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology	25
Prognostic significance of pretreatment 18F-FDG PET/CT in hepatocellular carcinoma: A systematic review and meta-analysis	25
Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet	25
Does ammonia really disrupt brain oxygen homeostasis?	24
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆	24
Good long-term outcomes of primary sclerosing cholangitis in childhood	24
Hepatocellular carcinoma: Epidemiology, diagnosis and treatment	24
Development and patterns of acute-on-chronic liver failure in patients with cirrhosis and acute kidney injury	23
Serum proteomics of adults with acute liver failure provides mechanistic insights and attractive prognostic biomarkers	23
Guideline-enhanced large language models outperform physician-test takers on EASL Campus quizzes multiple choice questions	23
Adipose microsomal triglyceride transfer protein deficiency protects against hepatic steatosis by upregulating PPARα activity	23
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma	23
Myeloid TGF-β signaling shapes liver macrophage heterogeneity and metabolic liver disease pathogenesis	23
Resolvin D1-mediated cellular crosstalk protects against MASH	23
Diagnostic accuracy of transient elastography in MASLD is independent of MRI-PDFF steatosis in a multicenter study	23
External beam radiation for HCC: Ready for incorporation into guidelines?	22
Copyright and information	22
Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis	22
Time-restricted eating, liver health, and fecal microbiota in adults with overweight or obesity: a randomized controlled trial	22
Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis	22
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies	22
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis	22
Elevation of liver elasticity following radiofrequency ablation reflects neutrophil-mediated abscopal effect in liver cancer	22
Prevalence of Rocahepevirus ratti (rat hepatitis E virus) in humans and rats in China	22
Orphan drug uttroside B impedes MASH progression and HCC development in experimental models	22
Small molecule drugs promote repopulation of transplanted hepatocytes by stimulating cell dedifferentiation	22
Alcohol intake reprograms hepatic immune-metabolic circuits to exacerbate murine atherosclerosis and human cardiovascular risk	22
Contents	22
Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma	22
Reply to: “Extending the Baveno VII definition of recompensation to autoimmune hepatitis: Considerations regarding treatment timing and response criteria”	22
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort	21
Editorial Board page	21
H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression	21
Copyright and information	21
Corrigendum to “Missed opportunities in HCV care: Trends in late diagnosis and treatment” [JHEP Reports 7 (2025) 101474]	21
Innovative approaches to the management of ascites in cirrhosis	21
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab	21
Corrigendum to “Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study” [JHEP Reports 2025 7(10) 101516]	21
Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis	21
LAPTM4B enhances the stemness of CD133+ liver cancer stem-like cells via WNT/β-catenin signaling	21
Copyright and information	20
The multi-omic basis for hepatic encephalopathy recurrence: Analysis of the THEMATIC trial	20
Circadian control of ConA-induced acute liver injury and inflammatory response via Bmal1 regulation of Junb	20
Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: Post hoc analysis of the PROSPER trial	20
Temporal trends and racial/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022	20
Acknowledging our reviewers	20
QuickStroop for screening for minimal hepatic encephalopathy in patients with cirrhosis	20
Thyroid dysfunction in MASLD: Results of a nationwide study	20
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis	20
Transcriptomics unveils immune metabolic disruption and a novel biomarker of mortality in patients with HBV-related acute-on-chronic liver failure	20
Should all pediatric patients with type 1 autoimmune hepatitis be screened for inflammatory bowel disease?	20
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis	20
DHCR7 inhibition ameliorates MetALD and HCC in mice and human 3D liver spheroids	20
Contents	19
Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis	19

Interleukin-8–driven monocyte activation in primary sclerosing cholangitis: Insights from single-cell analysis and humanized immune system mice	19
Alcohol-driven phenotypic transition in MASLD and risk of liver-related events	19
The ‘social gradient' in primary liver cancer in France: A national observational study	19
Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation	19
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison	19
Spatial-quantitative profiling of intrahepatic HBsAg heterogeneity and clustered distribution in chronic HBV infection	19
Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies	19
Contents	19
Challenges in the diagnosis and treatment of genetic cholestasis in adults	19
Evolving epidemiology of HCC in Spain	19
Reply to: “Enhancing biliary protection via HOPE: Beyond bile composition to cholangiocyte resilience”	19
Editorial Board page	18
Compression pressure of the external jugular vein for the assessment of intravascular volume status in decompensated cirrhosis: A pilot study	18
Dyrk2 gene transfer suppresses hepatocarcinogenesis by promoting the degradation of Myc and Hras	18
Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1	18
Contents	18
Corrigendum to ‘Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation’ [JHEP Reports 6 (2024) 100983]	18
Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice	18
B4GALNT1 promotes hepatocellular carcinoma stemness and progression via integrin α2β1-mediated FAK and AKT activation	18
Editorial Board page	18
Contents	18
Primary sclerosing cholangitis pathogenesis revisited: EBV-idence of immune dysregulation	18
Spatial profiling defines three immunophenotypes and a perineural invasion-associated immune-evasion niche in gallbladder cancer	18
Reply to: “Statins in MASLD: Challenges and future directions”	18
Erratum to ‘Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease’ (JHEP Reports 5 [2023] 100836)	17
Distribution of non-ceruloplasmin-bound copper after i.v. 64Cu injection studied with PET/CT in patients with Wilson disease	17
Accurate detection of cholangiocarcinoma in primary sclerosing cholangitis using DNA methylation biomarkers in bile and plasma	17
Underuse of statins in MASLD despite population-based associations with lower liver stiffness	17
Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease	17
Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort	17
Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer	17
Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes	17
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis	17
Genome-wide meta-analysis identifies nine loci associated with higher risk of hepatocellular carcinoma development	17
Single-cell analysis of mature hepatocytes reveals an IRF1-driven restriction of HDV infection	17
Traditional lifestyle factors partly mediate the association of socioeconomic position with intrahepatic lipid content: The Maastricht study	17
Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis	17
Making space and opportunities for talent to grow	17
Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study	17
Liver specification of human iPSC-derived endothelial cells transplanted into mouse liver	17
A thioacrylamide-based compound directly counteracts hepatic fibrosis with profound anti-obesity action	16
Editorial Board page	16
A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice	16
Contents	16
SBRT for bridging and downstaging HCC before transplant	16
Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component	16
Waiting time dictates impact of frailty: A Spanish multicenter prospective study	16
Kinase suppressor of Ras 1 (KSR1) promotes liver carcinogenesis via activation of the RAS/RAF/MEK/ERK signaling pathway	16
3D endothelial cell scaffolds protect liver explants and exhibit therapeutic effects on liver fibrosis	16
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study	16
Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy	16
Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?	16
Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma	16
ABCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome	16
Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials	15
Transcriptomic landscapes of effective and failed liver regeneration in humans	15
Actin-specific smooth muscle antibodies bridge adult and juvenile autoimmune hepatitis diagnosis	15
Endoscopic ultrasound-guided portosystemic pressure gradient measurement vs. transjugular balloon occlusion measurement in patients with cirrhosis (ENCOUNTER): A bicentric EU study	15
Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation	15
A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications	15
NTCP ubiquitination enables HBV infection	15
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis	15
Characterisation of forkhead box protein A3 as a key transcription factor for hepatocyte regeneration	15
Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging	15
Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease	15
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC	15
Phosphatidylethanol improves diagnostic accuracy of MASLD, MetALD, and ALD: Results from a prospective cohort study	15
Refined liver MRI-derived cT1 thresholds capturing hepatic fat fraction enhance mortality risk prediction	15
A hepatocyte-derived GPNMB–RYK signaling axis in MASH progression	15
AI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomes	15
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort	15
Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease	14
Ketamine restriction correlates with reduced cholestatic liver injury and improved outcomes in critically ill patients with burn injury	14
Risk of portal hypertensive complications preventable by TIPS in patients with ascites	14
Reply to: “Ductular reaction is a prognostic factor in primary biliary cholangitis”	14
Rethinking risk indices in pediatric MASLD	14
Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia	14
Infection prevention and control programme and COVID-19 measures: Effects on hospital-acquired infections in patients with cirrhosis	14
Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)	14
Contents	14
Copyright and information	14
Liver biopsy quality criteria to exclude cirrhosis in case of suspicion of porto-sinusoidal vascular disorder	14
Hepatic venous pressure gradient in sinusoidal obstruction syndrome: Diagnostic value and link with histological lesions	14
Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)	14
Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study	14
Editorial Board page	14
Contents	14
Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly	14
Pre-liver transplant assessment of patients with acute-on-chronic liver failure: An international survey	14
Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report	13
Contents	13
Implementing a new HCV model of care for people who use drugs	13
Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome	13
Contents	13
Editorial Board page	13